ArticleHepatology (Baltimore, Md.)2020
Impact of Alcohol Use Disorder Treatment on Clinical Outcomes Among Patients With Cirrhosis.
Article in Hepatology (Baltimore, Md.), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06471686 (Safety of Acamprosate in Treating Alcohol Use Disorder in the Post Liver Transplant Populations), which is not on this map. Cited by 106 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Safety of Acamprosate in Treating Alcohol Use Disorder in the Post Liver Transplant Populations
Who cites it
106 citing papers in PubMed, 5 syntheses or guidelines pooled it, 208 citations in OpenAlex.
- Psychosocial therapy improves outcomes for alcohol use disorder in people with chronic liver disease: A systematic review and meta-analysis.Hepatology communications · 2025Pooled it
- Pharmacological therapies for alcohol use disorder reduce hepatic decompensation & mortality in alcohol-related liver disease: A GRADE evaluation through a meta-analysis.The Indian journal of medical research · 2025Pooled it
- Treatment of alcohol use disorder in alcohol-associated liver disease: A meta-analysis.Hepatology communications · 2025Pooled it
- Meta-analysis: Prevalence and impact of alcohol abstinence in alcohol-associated cirrhosis.Alimentary pharmacology & therapeutics · 2024Pooled it
- Simultaneous Management of Alcohol Use Disorder and Liver Disease: A Systematic Review and Meta-analysis.Journal of addiction medicinePooled it
- Detection of undiagnosed liver cirrhosis via AI-enabled electrocardiogram: a pragmatic, cluster-randomized clinical trial.Nature medicine · 2026Trial
- Contingency management to promote treatment engagement in comorbid alcohol use disorder and alcohol-related liver disease: Findings from a pilot randomized controlled trial.Alcohol, clinical & experimental research · 2025Trial
- What hepatology clinicians and their patients with alcohol-related liver disease think of wearable alcohol biosensors to aid abstinence from alcohol: A qualitative study.Drug and alcohol review · 2025Trial
- The Importance of Addiction Medicine Education for Emergency Medicine Residents and Opportunities to Increase Uptake of Evidence-Based Interventions for Substance Use Disorder.Annals of emergency medicine · 2026Article
- Implementation of Mobile-Based Programs for Alcohol Cessation in the Treatment of Alcohol-associated Liver Disease: Protocol for a Type 1 Hybrid Implementation-Effectiveness Trial.JMIR research protocols · 2026Article
- Provider attitudes, practices, and barriers in alcohol-associated liver disease care: Findings from the CASL ALD SIG national survey.Canadian liver journal · 2026Article
- Integrated behavioral care in general hepatology increases alcohol use disorder treatment in veterans.Hepatology communications · 2026Article
- Metabolic Reprogramming Driven by Modifiable Lifestyle Factors in Metabolic Syndrome and Alcohol-Related Liver Disease: A Narrative Review.Metabolites · 2026Review
- Early liver transplantation in alcohol-associated liver disease-Evolution of practice, patient selection, management, and outcomes.Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society · 2026Review
- Medications for Alcohol Use Disorder Among Patients With Severe Alcohol-Related Liver Disease.JAMA network open · 2026Article
- Krüppel-like factor 15 ameliorates alcohol-induced liver injury in mice via regulation of the PFKFB3/AKT axis.Acta pharmacologica Sinica · 2026Article
- Care Coordination for Patients Admitted With Alcohol-Associated Liver Disease: An Assessment of Appropriate Follow-up and Treatment at Time of Discharge.Gastro hep advances · 2026Article
- Enhancement of Inpatient Mortality Prognostication With Machine Learning in a Prospective Global Cohort of Patients With Cirrhosis With External Validation.Gastroenterology · 2026Article
- An Update on IL-22 Therapies in Alcohol-Associated Liver Disease and Beyond.The American journal of pathology · 2026Review
- Proactive case-finding and risk-stratification in people at risk of chronic liver disease in Greater Manchester: a cost-effectiveness analysis.BMJ public health · 2026Article
46 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
11 authors at 4 institutions in 1 country.
Funding
Abstract
BACKGROUND AND
aimsDespite the significant medical and economic consequences of coexisting alcohol use disorder (AUD) in patients with cirrhosis, little is known about AUD treatment patterns and their impact on clinical outcomes in this population. We aimed to characterize the use of and outcomes associated with AUD treatment in patients with cirrhosis. APPROACH AND
resultsThis retrospective cohort study included Veterans with cirrhosis who received Veterans Health Administration care and had an index diagnosis of AUD between 2011 and 2015. We assessed the baseline factors associated with AUD treatment (pharmacotherapy or behavioral therapy) and clinical outcomes for 180 days following the first AUD diagnosis code within the study time frame. Among 93,612 Veterans with cirrhosis, we identified 35,682 with AUD, after excluding 2,671 who had prior diagnoses of AUD and recent treatment. Over 180 days following the index diagnosis of AUD, 5,088 (14%) received AUD treatment, including 4,461 (12%) who received behavioral therapy alone, 159 (0.4%) who received pharmacotherapy alone, and 468 (1%) who received both behavioral therapy and pharmacotherapy. In adjusted analyses, behavioral and/or pharmacotherapy-based AUD treatment was associated with a significant reduction in incident hepatic decompensation (6.5% vs. 11.6%, adjusted odds ratio [AOR], 0.63; 95% confidence interval [CI], 0.52, 0.76), a nonsignificant decrease in short-term all-cause mortality (2.6% vs. 3.9%, AOR, 0.79; 95% CI, 0.57, 1.08), and a significant decrease in long-term all-cause mortality (51% vs. 58%, AOR, 0.87; 95% CI, 0.80, 0.96).
conclusionsMost Veterans with cirrhosis and coexisting AUD did not receive behavioral therapy or pharmacotherapy treatment for AUD over a 6-month follow-up. The reductions in hepatic decompensation and mortality suggest that future studies should focus on delivering evidence-based AUD treatments to patients with coexisting AUD and cirrhosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.